Endeavor

Dendritic Cell Vaccines Changing Landscape for Breast Cancer Treatment

Moffitt research shows promise in breakthrough immunotherapy treatment

Improving Outcomes for Patients With Synovial Sarcoma

Moffitt treats first patient in the world with FDA-approved Tecelra

Navigating Survivorship After Bone and Marrow Transplant

Moffitt experts and leukemia survivor share candid insights and support resources

Moffitt Cancer Center Is One of the Nation’s Best Cancer Hospitals

Top ranked cancer center in Florida and the Southeast, based on U.S. News & World Report

Next-Gen Cell Therapy Shows Lasting Remission for Older Adults with Aggressive Leukemia

Recently approved obe-cel continues to deliver high remission rates and durable responses in patients once considered too high-risk for immunotherapy

New Immunotherapy Strategy Improves Outcomes in Patients with Advanced Head and Neck Cancer

Patients treated with pembrolizumab were at least 27% less likely to experience cancer recurrence or death

Moffitt Launches Immunotherapy Podcast

Monthly series highlights visionaries in immunotherapy and the breakthroughs that are transforming lives

Business of Biotech Attracts Record Numbers

Executives, entrepreneurs, venture capitalists, angel investors and researchers from across the U.S. gather for unique opportunity to collaborate

Are Personalized Vaccines the Future of Triple-Negative Breast Cancer Treatment?

Moffitt studies the use of dendritic cell vaccines to harness the immune system